Third-line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource-limited settings: ACTG A5288 strategy trial.
Avihingsanon A, Hughes MD, Salata R, Godfrey C, McCarthy C, Mugyenyi P, Hogg E, Gross R, Cardoso SW, Bukuru A, Makanga M, Badal-Aesen S, Mave V, Ndege BW, Fontain SN, Samaneka W, Secours R, Van Schalkwyk M, Mngqibisa R, Mohapi L, Valencia J, Sugandhavesa P, Montalban E, Munyanga C, Chagomerana M, Santos BR, Kumarasamy N, Kanyama C, Schooley RT, Mellors JW, Wallis CL, Collier AC, Grinsztejn B; A5288 Study team.
Avihingsanon A, et al. Among authors: wallis cl.
J Int AIDS Soc. 2022 Jun;25(6):e25905. doi: 10.1002/jia2.25905.
J Int AIDS Soc. 2022.
PMID: 36039892
Free PMC article.
At 48 weeks, 87% of these participants achieved HIV-1 RNA 200 copies/ml. We report here long-term outcomes over 144 weeks. METHODS: Study participants were enrolled from 2013 to 2015, prior to the availability of dolutegravir in LMICs. ...
At 48 weeks, 87% of these participants achieved HIV-1 RNA 200 copies/ml. We report here long-term outcomes over 144 weeks. METHODS: S …